Raf pathway inhibitors in oncology

Current Opinion in Investigational Drugs

Volumn 4, Issue 12, 2003, Pages 1436-1441

  Bollag, Gideon ^a,b   Freeman, Scott ^b   Lyons, John F ^b,c   Post, Leonard E ^b  

^a PLEXXIKON INC   (United States)

^b ONYX PHARMACEUTICALS   (United States)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

BAY 43 9006; Kinase inhibitors; MEK; Raf; Ras

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; B RAF KINASE; BENZYLIDENE OXINDOLE DERIVATIVE; CARBOPLATIN; CGP 69846A; DORAMAPIMOD; GEMCITABINE; GROWTH FACTOR RECEPTOR; L 779450; LIPOSOMAL RAF ANTISENSE OLIGONUCLEOTIDE; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PACLITAXEL; PHOSPHOTRANSFERASE; PROTEIN KINASE INHIBITOR; RAF 1 KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOXICITY; ENZYME ACTIVITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; ONCOLOGY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SKIN TOXICITY; TUMOR; TUMOR CELL;

ANIMALS; BENZENESULFONATES; ENZYME INHIBITORS; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RAF; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 1642556736     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Chong H, Vikis HG, Guan KL: Mechanisms of regulating the Raf kinase family. Cell Signal (2003) 15(5):463-469.
2. Mercer KE, Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta (2003) 1653(1):25-40.
3. Katz ME, McCormick F: Signal transduction from multiple Ras effectors. Curr Opin Genet Dev (1997) 7(1):75-79.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417(6892):949-954. Paper describing the seminal discovery of BRAF mutations in human tumors and further demonstrating that these mutations are activating.
5. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 63(7):1454-1457.
6. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G et al.: High frequency of BRAF mutations in nevi. Nat Genet (2003) 33(1):19-20. Description of frequent BRAF mutations in benign melanocytic nevi suggests a possible role in early stage tumorigenesis.
7. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res (2003) 63(14):3883-3885. Report that BRAF mutations are infrequent in early stage melanomas, suggesting a role in progression.
8. 601. EMBO J (2000) 19(20):5429-5439.
9. Storm SM, Rapp UR: Oncogene activation: c-Raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett (1993) 67(1-3):201-210.
10. Hüser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R, Pritchard C: MEK kinase activity is not necessary for Raf-1 function. EMBO J (2001) 20(8):1940-1951.
11. Lee JT, McCubrey JA: BAY-43-9006 Bayer/Onyx. Curr Opin Invest Drugs (2003) 4(6):757-763.
12. Lowinger TB, Riedl B, Dumas J, Smith RA: Design and discovery of small molecules targeting Raf-1 kinase. Curr Pharm Des (2002) 8(25):2269-2278. Paper detailing the chemistry leading to the discovery of BAY-43-9006.
13. Lyons JF, Wilhelm S, Hibner B, Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer (2001) 8(3):219-225.
14. Dumas J: Protein kinase inhibitors from the urea class. Curr Opin Drug Discovery Dev (2002) 5(3):718-727.
15. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 9(4):268-272. First crystallographic description of a bis-aryl urea binding to a kinase.
16. Wilhelm S, Chien DS: BAY 43-9006: Preclinical data. Curr Pharm Des (2002) 8(25):2255-2257.
17. Strumberg D, Awada A, Piccart M, Hirte H, Moore M, Clark J, Lenz H-J, Lathia C, Coppieters S, Humphrey R: Final report of the phase I clinical program of the novel Raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors. Proc Am Soc Clin Oncol (2003) 22:Abs 813.
18. Chow S, Patel H, Hedley DW: Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry (2001) 46(2):72-78.
19. Flaherty KT, Lee RJ, Humphries R, O'Dwyer PJ, Schiller J: Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Proc Am Soc Clin Oncol (2003) 22:Abs 2854.
20. Tuveson DA, Weber BL, Herlyn M: BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell (2003) 4(2):95-98.
21. Siu L, Awada A, Takimoto CH, Moore MJ, Piccart M, Fiander W, Lathia C, Petrenciuc O: Phase I study of oral Raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol (2003) 22:Abs 828.
22. Ratain MJ, O'Dwyer P, Stadler W, Kaye S, Xiong H, Eisen T, Patnaik A, Smith M, Flaherty KT, Kindler H, Lee RJ et al. : A phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer. Proc Int Symp Signal Transduction Modulators Cancer Ther (2003) 2:Abs O24
23. Lackey K, Cory M, Davis R, Frye SV, Harris PA, Hunter RN, Jung DK, McDonald OB, McNutt RW, Peel MR, Rutkowske RD et al.: The discovery of potent cRaf1 kinase inhibitors. Bioorg Med Chem Lett (2000) 10(3):223-226.
24. Wood E, Crosby RM, Dickerson S, Frye SV, Griffin R, Hunter R, Jung DK, McDonald OB, McNutt R, Mahony WB, Peel MR et al.: A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity. Anticancer Drug Des (2001) 16(1):1-6.
25. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P: Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 6(8):559-568.
26. Heimbrook DC, Huber HE, Stirdivant SM, Claremon D, Liverton N, Patrick DR, Selnick H, Ahern J, Conroy R, Drakas R, Falconi N et al.: Identification of potent, selective kinase inhibitors of Raf. Proc Annu Meet Am Assoc Cancer Res (1998) 39:Abs 3793.
27. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med (1996) 2(6):668-675.
28. O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS: c-Raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res (1999) 5(12):3977-3982.
29. Gokhale PC, Zhang C, Newsome JT, Pei J, Ahmad I, Rahman A, Dritschilo A, Kasid UN: Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin Cancer Res (2002) 8(11):3611-3621.
30. Kasid U, Dritschilo A: raf antisense oligonucleotide as a tumor radiosensitizer. Oncogene (2003) 22(37):5876-5884.
31. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, Sakamuri S et al.: Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci USA (2002) 99(22):14398-14403.
32. English JM, Cobb MH: Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci (2002) 23(1):40-45.
33. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA (1995) 92(17):7686-7689. Discovery of the ubiquitously utilized MEK inhibitor PD-98059.
34. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem (1995) 270(46);27489-27494.
35. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA et al.: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 273(29):18623-18632.
36. Berger D, Dutia M, Powell D, Wu B, Wissner A, Boschelli DH, Floyd MB, Zhang N, Torres N, Levin J, Du X et al.: Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. Bioorg Med Chem Lett (2003) 13(18):3031-3034.
37. Zhang N, Wu B, Eudy N, Wang Y, Ye F, Powell D, Wissner A, Feldberg LR, Kim SC, Mallon R, Kovacs ED et al.: MEK (MAPKK) inhibitors. Part 2: Structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines. Bioorg Med Chem Lett (2001) 11(11):1407-1410.
38. Zhang N, Wu B, Powell D, Wissner A, Floyd MB, Kovacs ED, Toral-Barza L, Kohler C: Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors. Bioorg Med Chem Lett (2000) 10(24):2825-2828.
39. Boschelli DH: 4-Anilino-3-quinolinecarbonitriles: An emerging class of kinase inhibitors. Curr Top Med Chem (2002) 2(9):1051-1063.
40. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 5(7):810-816. Paper detailing the elegant characterization of the MEK inhibitor PD-184352.
41. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J: In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum (2003) 48(6):1582-1593.
42. Ciruela A, Dixon AK, Bramwell S, Gonzalez MI, Pinnock RD, Lee K: Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol (2003) 138(5):751-756.
43. LoRusso PM, Adjei AA, Meyer MB, Wozniak A, Gadgeel SM, Hanson LJ, Reid JM, Mitchell DY, Bruzek LM, Sebolt-Leopold JS, Herrera R et al.: A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol (2002) 21:Abs 321.
44. Waterhouse DM, Rinehart J, Adjei AA, Hecht JR, Natale RB, LoRusso PM, Asbury PC, Hamid O, Gulyas S, Meyer MB: A phase 2 study of an oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, or pancreatic cancer. Proc Am Soc Clin Oncol (2003) 22:Abs 816.
45. Omer CA, Sebolt-Leopold JS: The promise of MEK1/2 inhibitors in molecular-based cancer therapy. Proc Int Symp Signal Transduction Modulators Cancer Ther (2003) 2:Abs O.31.